生物标志物能正确预测心脏骤停后接受目标温度管理的患者中的呼吸机相关性肺炎吗?多中心随机抗生素(ANTHARTIC)研究的探索性分析
这是一项前瞻性辅助研究,依托多中心、随机、双盲、安慰剂对照的ANTHARTIC试验,评估抗生素预防对院外心脏骤停(可除颤心律)并接受治疗性低温患者VAP的影响。由裁定委员会依据预设临床、影像和微生物学标准盲法判定VAP,共纳入161例有可用生物标志物样本的患者,其中VAP 33例、无VAP 121例。VAP组体重指数和APACHE II评分更高、更多为无人目击的心脏骤停、更多使用儿茶酚胺、治疗性低温持续时间更长。单变量分析中CRP(AUC=0.76)、IL17A与IL17C(0.74)、巨噬细胞集落刺激因子1(0.73)、PCT(0.72)、VEGF-A(0.71)与VAP显著相关且AUC>0.70;多变量分析中多种新型生物标志物两两组合的P值小于0.001且比值比大于1,最佳AUC为CRP+IL6(0.79)、CRP+CCL20(0.78)以及CRP+IL17A、CRP+IL17C。作者认为,特定生物标志物尤其CRP联合IL6可能有助于更好地诊断或预测心脏骤停患者早期VAP的发生。
要点
- 在161例心脏骤停后接受目标温度管理的患者中,VAP 33例、无VAP 121例,VAP组体重指数和APACHE II评分更高、更多为无人目击的心脏骤停、更多使用儿茶酚胺、治疗性低温持续时间更长。
- 单变量分析中与VAP显著相关且AUC>0.70的生物标志物:CRP(AUC=0.76)、IL17A与IL17C(0.74)、巨噬细胞集落刺激因子1(0.73)、PCT(0.72)、VEGF-A(0.71)。
- 多变量分析中新型生物标志物两两组合的P值小于0.001且比值比大于1,包括VEGF-A+IL12B、Flt3L+CCL20、Flt3L+IL17A、Flt3L+IL6、STAMBP+CCL20、STAMBP+IL6、CCL20+4EBP1、CCL20+CASP8、IL6+4EBP1、IL6+CASP8。
- 最佳AUC见于CRP+IL6(0.79)、CRP+CCL20(0.78)以及CRP+IL17A、CRP+IL17C。
- 作者认为,特定生物标志物尤其CRP联合IL6可能有助于更好地诊断或预测心脏骤停患者早期VAP的发生。
适用人群与场景
- 院外心脏骤停、可除颤心律、接受治疗性低温和目标温度管理的患者(ANTHARTIC试验人群)。
- 纳入标准:有可用生物标志物样本且知情同意获批的患者。
诊断标准与关键阈值
- VAP由裁定委员会依据预设临床、影像和微生物学标准盲法判定。
研究设计与关键结果
- 研究设计:多中心随机双盲安慰剂对照ANTHARTIC试验的前瞻性辅助研究;共纳入161例有可用生物样本的患者,VAP 33例、无VAP 121例;第3天采血,盲法检测常规和探索性炎症生物标志物 panel,分析按随机分组校正。
- 主要终点:评估生物标志物在采样后48小时内正确诊断和预测VAP的能力;次要终点:研究两种生物标志物组合鉴别VAP。
- VAP组 vs 无VAP组:体重指数和APACHE II评分更高、更多为无人目击的心脏骤停、更多使用儿茶酚胺、治疗性低温持续时间更长。
- 单变量分析中与VAP显著相关且AUC>0.70:CRP(AUC=0.76)、IL17A与IL17C(0.74)、巨噬细胞集落刺激因子1(0.73)、PCT(0.72)、VEGF-A(0.71)。
- 多变量分析中新型生物标志物两两组合P值小于0.001且比值比大于1:VEGF-A+IL12B、Flt3L+CCL20、Flt3L+IL17A、Flt3L+IL6、STAMBP+CCL20、STAMBP+IL6、CCL20+4EBP1、CCL20+CASP8、IL6+4EBP1、IL6+CASP8。
- 最佳AUC:CRP+IL6(0.79)、CRP+CCL20(0.78)以及CRP+IL17A、CRP+IL17C。
证据类型、等级与局限
- 证据类型:多中心随机双盲安慰剂对照试验的前瞻性探索性辅助研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,特定生物标志物尤其CRP联合IL6可能有助于更好地诊断或预测心脏骤停患者早期VAP的发生。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Ventilator-associated pneumonia (VAP) frequently occurs in patients with cardiac arrest. Diagnosis of VAP after cardiac arrest remains challenging, while the use of current biomarkers such as C-reactive protein (CRP) or procalcitonin (PCT) is debated.
OBJECTIVES: To evaluate biomarkers' impact in helping VAP diagnosis after cardiac arrest.
DESIGN SETTING AND PARTICIPANTS: This is a prospective ancillary study of the randomized, multicenter, double-blind placebo-controlled ANtibiotherapy during Therapeutic HypothermiA to pRevenT Infectious Complications (ANTHARTIC) trial evaluating the impact of antibiotic prophylaxis to prevent VAP in out-of-hospital patients with cardiac arrest secondary to shockable rhythm and treated with therapeutic hypothermia. An adjudication committee blindly evaluated VAP according to predefined clinical, radiologic, and microbiological criteria. All patients with available biomarker(s), sample(s), and consent approval were included.
MAIN OUTCOMES AND MEASURES: The main endpoint was to evaluate the ability of biomarkers to correctly diagnose and predict VAP within 48 hours after sampling. The secondary endpoint was to study the combination of two biomarkers in discriminating VAP. Blood samples were collected at baseline on day 3. Routine and exploratory panel of inflammatory biomarkers measurements were blindly performed. Analyses were adjusted on the randomization group.
RESULTS: Among 161 patients of the ANTHARTIC trial with available biological sample(s), patients with VAP (n = 33) had higher body mass index and Acute Physiology and Chronic Health Evaluation II score, more unwitnessed cardiac arrest, more catecholamines, and experienced more prolonged therapeutic hypothermia duration than patients without VAP (n = 121). In univariate analyses, biomarkers significantly associated with VAP and showing an area under the curve (AUC) greater than 0.70 were CRP (AUC = 0.76), interleukin (IL) 17A and 17C (IL17C) (0.74), macrophage colony-stimulating factor 1 (0.73), PCT (0.72), and vascular endothelial growth factor A (VEGF-A) (0.71). Multivariate analysis combining novel biomarkers revealed several pairs with p value of less than 0.001 and odds ratio greater than 1: VEGF-A + IL12 subunit beta (IL12B), Fms-related tyrosine kinase 3 ligands (Flt3L) + C-C chemokine 20 (CCL20), Flt3L + IL17A, Flt3L + IL6, STAM-binding protein (STAMBP) + CCL20, STAMBP + IL6, CCL20 + 4EBP1, CCL20 + caspase-8 (CASP8), IL6 + 4EBP1, and IL6 + CASP8. Best AUCs were observed for CRP + IL6 (0.79), CRP + CCL20 (0.78), CRP + IL17A, and CRP + IL17C.
CONCLUSIONS AND RELEVANCE: Our exploratory study shows that specific biomarkers, especially CRP combined with IL6, could help to better diagnose or predict early VAP occurrence in cardiac arrest patients.
参考来源
- Deye N, Le Gouge A, François B, et al. Can Biomarkers Correctly Predict Ventilator-associated Pneumonia in Patients Treated With Targeted Temperature Management After Cardiac Arrest? An Exploratory Study of the Multicenter Randomized Antibiotic (ANTHARTIC) Study. Crit Care Explor. 2024. PMID: 38957212. doi:10.1097/CCE.0000000000001104
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。